US Stock MarketDetailed Quotes

OCGN Ocugen

Watchlist
  • 1.2600
  • -0.0700-5.26%
Close Jun 24 16:00 ET
  • 1.2500
  • -0.0100-0.79%
Post 19:57 ET
324.27MMarket Cap-5478P/E (TTM)

About Ocugen Company

Ocugen, Inc. is a biopharmaceutical company, which engages in the development and commercialization of therapies to cure eye diseases. Its product pipeline candidates include OCU400, OCU410, OCU200, and COVAXIN. The firm's modifier gene therapy platform is engaged in addressing retinal diseases, including retinitis pigmentosa, leber congenital amaurosis, and dry age-related macular degeneration. The company was founded by Shankar Musunuri and Uday B. Kompella in 2013 and is headquartered in Malvern, PA.

Company Profile

SymbolOCGN
Company NameOcugen
Listing DateDec 3, 2014
Issue Price11.00
Founded2013
CEODr. Shankar Musunuri, M.B.A.,PhD
MarketNASDAQ
Employees65
Securities TypeOrdinary Shares
Fiscal Year Ends12-31
Address11 Great Valley Parkway
CityMalvern
ProvincePennsylvania
CountryUnited States of America
Zip Code19355
Phone1-484-328-4701

Company Executives

  • Name
  • Position
  • Salary
  • Dr. Shankar Musunuri, M.B.A.,PhD
  • Chairman of the Board and Chief Executive Officer
  • 7.66M
  • Michael Breininger
  • Corporate Controller, Interim Chief Accounting Officer and Principal Financial Officer
  • --
  • Arun Upadhyay
  • Chief Scientific Officer and Head of Research, Development, and Medical
  • --
  • Dr. Prabhavathi Fernandes, PhD
  • Independent Director
  • 357.60K
  • Kirsten Castillo
  • Independent Director
  • 348.18K
  • Dr. Junge Zhang, PhD
  • Independent Director
  • 335.56K
  • Dr. Ramesh Kumar, PhD
  • Independent Director
  • 347.28K
  • Dr. Marna C. Whittington
  • Independent Director
  • 649.56K
  • Uday B. Kompella, PhD
  • Independent Director
  • 341.82K

Analysis

Analyst Rating

No Data

Price Target

No Data

Heat List
US
Overall
Symbol
Latest Price
%Chg